文献速递间质性肺疾病

是时候改变了:特发性肺纤维化是否仍为特发且仅纤维化?

Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
PubMed 文献 · Lancet Respir Med · 2018-01-01

该观点文章回顾了特发性肺纤维化(IPF)的命名与分类历史,结合对其临床表现、病因和发病机制的理解,指出远端气道与肺泡上皮细胞是疾病的核心驱动因素。作者旨在引发关于在临床、遗传、细胞和分子机制取得重大进展后是否应更改病名的讨论,并提出更新疾病名称和分类所有形式肺纤维化的新建议。

要点

  • IPF以胸膜下纤维化、上皮下成纤维细胞灶和镜下蜂窝样变为特征。
  • 远端气道与肺泡上皮细胞被认为是IPF的核心驱动因素。
  • 作者建议讨论更改IPF病名并更新肺纤维化分类方法。

核心结论

  • 鉴于对IPF临床、遗传、细胞和分子机制的理解取得重大进展,应考虑更改病名并更新肺纤维化分类。

研究设计与样本

  • 本文为观点文章,回顾用于定义现称IPF的命名和分类历史,并讨论是否应更改病名。

主要发现

  • IPF是进行性、不可逆且通常致命的肺部疾病,特征为胸膜下纤维化、上皮下成纤维细胞灶和镜下蜂窝样变。
  • 证据表明远端气道和肺泡上皮细胞是IPF的核心驱动因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Idiopathic pulmonary fibrosis (IPF) is a progressive, irreversible, and typically fatal lung disease characterised by subpleural fibrosis, subepithelial fibroblast foci, and microscopic honeycombing. Although understanding of the pathogenic mechanisms continues to evolve, evidence indicates that distal airway and alveolar epithelial cells are central drivers of the disease. In this Viewpoint, we review the history of naming and classifications used to define the disease now referred to as IPF, in the context of understanding the clinical presentation, causes, and pathogenesis of the disease. We aim to generate discussion on whether, given the substantial progress made in understanding the clinical, genetic, cellular, and molecular mechanisms involved in the development of IPF, a change of name should be considered. To initiate this discussion, we offer new suggestions to update the name of this disease and new approaches to classify all forms of pulmonary fibrosis.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Wolters PJ, Blackwell TS, Eickelberg O, et al. Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med. 2018. PMID: 29413083. doi:10.1016/S2213-2600(18)30007-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。